Allocetra
Cell therapy
Evidence outlook
Osteoarthritis: topline reported 2025-08-18
The sponsor reported topline results on 2025-08-18 (Phase IIa stage of ENX-CL-05-001 (NCT06233474): positive three-month topline data in knee osteoarthritis). The announcement is listed under Regulatory events.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06233474 NCT06233474 · Osteoarthritis, Knee Registry: NCT06233474 | 1/2 | Treatment-emergent adverse events and Serious adverse events following Allocetra-OTS injection (7 months following Day 0) 2026-03-15 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Osteoarthritis: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Allocetra: this drug | Phase 2 | Cell therapy | Macrophage reprogramming | not yet graded | No reviewed efficacy summary in this indication | |
| Ecnoglutide | Phase 3 | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Eloralintide | Phase 3 | Peptide | Amylin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Orforglipron (Foundayo) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Vutiglabridin | Phase 2 | Small molecule | paraoxonase-2 (PON2) | not yet graded | No reviewed efficacy summary in this indication | |
| PLX-PAD | —(overall) | Cell therapy | Mesenchymal stem cells (immunomodulatory, pro-angiogenic) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Allocetra to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
February 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent